Impact of positron emission tomography with computed tomography for image-guided radiotherapy.


Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 02 12 2019
revised: 10 03 2020
accepted: 12 03 2020
pubmed: 15 4 2020
medline: 23 7 2020
entrez: 15 4 2020
Statut: ppublish

Résumé

Therapeutic effectiveness in radiotherapy is partly related to correct staging of the disease and then precise therapeutic targeting. Positron emission tomography (PET) allows the stage of many cancers to be determined and therefore is essential before deciding on radiation treatment. The definition of the therapeutic target is essential to obtain correct tumour control and limit side effects. The part of adaptive radiotherapy remains to be defined, but PET by its functional nature makes it possible to define the prognosis of many cancers and to consider radiotherapy adapted to the initial response allowing an increase over the entire metabolic volume, or targeted at a subvolume at risk per dose painting, or with a decrease in the dose in case of good response at interim assessment.

Identifiants

pubmed: 32284178
pii: S1278-3218(20)30076-7
doi: 10.1016/j.canrad.2020.03.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

362-367

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

V Isnardi (V)

Department of Nuclear Medicine, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France.

S Thureau (S)

Department of Radiotherapy and Medical Physic, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France; Department of Nuclear Medicine Cancer, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France; Laboratoire QuantIF EA4108-Litis, université de Rouen, Rouen, France. Electronic address: sebastien.thureau@chb.unicancer.fr.

P Vera (P)

Department of Nuclear Medicine Cancer, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France; Laboratoire QuantIF EA4108-Litis, université de Rouen, Rouen, France; Faculty of Medicine, université de Rouen Normandie, rue d'Amiens, 76000 Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH